GLI1 and cancer: Together with its broad pan-cancer pejorative prognostic value distinct from that of TGFB/GLI1/2/EMT/Stemness, suggests a potential therapeutic benefit for the combination of cytostatic drugs together with anti TGF-β/GLI inhibitors.